EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Real‐world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study ( RAILWAY )

Yayoi Tada, Akimichi Morita iD, Keiichi Yamanaka iD, Michihiro Kono iD, Shinichi Imafuku iD, Yukari Okubo iD, Fumikazu Yamazaki, Taisuke Kawamura, Asako Itakura, Mamitaro Ohtsuki

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16926 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Yayoi Tada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma K.K., Maruho Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic, immune‐mediated inflammatory skin disease with a high negative impact on patient's quality of life. Secukinumab, the first interleukin 17A inhibitor, has been used for the systemic treatment of psoriasis, but its long‐term, real‐world retention rates in Japan have not been fully investigated. In this multicenter, noninterventional, retrospective chart review study, the retention rate of secukinumab and its effectiveness among patients with psoriasis in Japan was evaluated up to 5 years. Data of patients who received secukinumab after December 26, 2014, were collected from medical charts obtained from seven sites, all certified for biologics use by the Japanese Dermatological Association. Patient characteristics, secukinumab retention, factors affecting secukinumab retention, reason for drug discontinuation, and effectiveness data were collected. The primary end point was secukinumab retention rate at week 52. A total of 123 patients were included in the analysis. Of these, 27 patients discontinued secukinumab by week 52, yielding a 78.0% (95% confidence interval, 69.6–84.4) retention rate at week 52. For patients whose Psoriasis Area and Severity Index (PASI) score was available, mean ± standard deviation PASI at baseline and at week 52 were 9.21 ± 7.37 and 1.4 ± 2.6, respectively. During the entire study period, “insufficient response” was the most common reason for discontinuation, and “history of biologics use” was a factor significantly associated with secukinumab discontinuation (hazard ratio, 1.72; p = 0.018). This study demonstrates the real‐world retention rate and effectiveness of secukinumab in patients with psoriasis in Japan for up to 5 years and provides clinical insights into psoriasis treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsHumansAntibodies, MonoclonalRetrospective StudiesQuality of LifeTreatment OutcomeSeverity of Illness IndexAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Japaninterleukin 17psoriasisretrospective studiessecukinumab

Substanzen

Antibodies, MonoclonalBiological ProductssecukinumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Dermatology and Plastic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
  • Department of Dermatology, Tokyo Medical University, Tokyo, Japan.

ORCID-Profile: Akimichi Morita, Keiichi Yamanaka, Michihiro Kono, Shinichi Imafuku, Yukari Okubo

Förderung

  • Novartis Pharma K.K.
  • Maruho Co., Ltd

Zitieren

APA

Tada, Y., Morita, A., Yamanaka, K., Kono, M., Imafuku, S., Okubo, Y., Yamazaki, F., Kawamura, T., Itakura, A., & Ohtsuki, M. (2023). Real‐world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study ( RAILWAY ). The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16926

Vancouver

Tada Y, Morita A, Yamanaka K, Kono M, Imafuku S, Okubo Y, et al. Real‐world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study ( RAILWAY ). The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16926

BibTeX
@article{Tada2023,
  author = {Tada, Yayoi and Morita, Akimichi and Yamanaka, Keiichi and Kono, Michihiro and Imafuku, Shinichi and Okubo, Yukari and Yamazaki, Fumikazu and Kawamura, Taisuke and Itakura, Asako and Ohtsuki, Mamitaro},
  title = {Real‐world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study ( RAILWAY )},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16926}
}
Kostenlos starten →